Morgan Stanley analyst Emmet Kelly resumed coverage of Cellnex with an Equal Weight rating and EUR 44 price target. The company’s organic growth story is underappreciated, but its step back from expansionary acquisitions removes an opportunity to "turbo-charge" its bottom line, Kelly tells investors in a research note.
Published first on TheFly
